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Objective
To identify predictors of nonsentinel node (NSN) tumor involve-
ment in patients with a tumor-involved sentinel node (SN).
Summary Background Data
For many breast cancer patients who undergo intraoperative
lymphatic mapping and sentinel lymphadenectomy (LM/SL),
the SN is the only tumor-involved axillary node. Associations
between NSN tumor involvement and several clinical and his-
topathologic factors have been identified. The authors hy-
pothesize that extracapsular extension (ECE) of the SN me-
tastasis is highly predictive of NSN tumor involvement.
Methods
Between May 1998 and December 2001, 260 patients (263
cases) with clinical T1 or T2 (5.0 cm) breast cancer under-
went LM/SL at the University of North Carolina, using a com-
bined blue dye and technetium sulfur colloid technique. In all
cases with a tumor-involved SN, axillary lymph node dissec-
tion (ALND) was recommended. Statistical analysis, with
Pearson chi-square tests, Fisher exact test, and multiple lo-
gistic regression, was performed.
Results
The SN contained tumor in 74 (28.1%) cases. ALND was per-
formed in 70 of the 74 cases. ECE of the SN metastasis was
present in 18 (25.7%) of the 70 cases. Patients with ECE of
the SN metastasis were more likely to have NSN tumor in-
volvement and had a greater total number of tumor-involved
nodes than patients without ECE of the SN metastasis. In-
creasing size of the SN metastasis and increasing size of the
primary tumor, examined as continuous variables, were asso-
ciated with an increased likelihood of NSN tumor involvement
on univariate analysis. However, only ECE of the SN metasta-
sis was associated with NSN tumor involvement on multivari-
ate analysis.
Conclusions
ECE of the SN metastasis is a strong predictor of NSN tumor
involvement. All patients with ECE of the SN metastasis
should undergo mandatory completion ALND.
Since Giuliano introduced intraoperative lymphatic map-
ping and sentinel lymphadenectomy (LM/SL) for breast
cancer patients in 1993,1 LM/SL has been emerging as the
standard of care for patients with T1 or T2 (5.0 cm) breast
cancer.2–7 Numerous institutions have demonstrated LM/SL
to be a highly accurate method for predicting the tumor
status of the axilla in patients with breast cancer. At insti-
tutions with a multidisciplinary sentinel node team com-
prised of nuclear medicine physicians, surgeons, and pa-
thologists, if the sentinel node (SN) is tumor-free, the
nonsentinel nodes (NSN) in the same axilla are highly
unlikely to contain metastatic breast cancer. As a result, at
centers with an experienced team, competent in LM/SL,
patients with a tumor-free SN do not need to undergo
completion axillary lymph node dissection (ALND).
However, when the SN reveals metastatic tumor, the
tumor status of the NSN in the remainder of the axilla
remains unknown. Consequently, to evaluate the NSN his-
topathologically, all patients with an SN metastasis must
undergo level I and II completion ALND. For patients with
a tumor-involved SN, the reported incidence of NSN tumor
involvement varies greatly (27–68%).2,3,5,6,8 As a result, if
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characteristics that reliably predict which patients with a
tumor-involved SN have a high likelihood of NSN tumor
involvement could be identified, it is possible that many
breast cancer patients with a tumor-involved SN would not
need to undergo completion ALND.
Several studies have attempted to identify predictors of
NSN metastases in patients with a tumor-involved SN. Size
of the primary tumor,9–17 size of the SN metasta-
sis,9–14,16,18,19 number of tumor-involved SNs,15,19 primary
tumor lymphovascular invasion (LVI),11,14,17,18 SN hilar
tumor invasion,14 and extracapsular extension (ECE) of the
SN metastasis18,20,21 have each been identified as predictors
of NSN tumor involvement. While the strength of most of
these predictors varies from study to study, ECE of the SN
metastasis, when examined, is consistently associated with
NSN tumor involvement.18,20,21
We first investigated predictors of NSN tumor involve-
ment when we completed our institutional validation trial
for LM/SL of breast cancer patients.21 We demonstrated
that ECE of the SN metastasis, which had not been previ-
ously examined by other investigators, was highly predic-
tive of NSN tumor involvement. Size of the SN metastasis
was also identified as a predictor of NSN metastases in our
initial series of patients. With our expanded LM/SL expe-
rience, we hypothesized that ECE of the SN metastasis and
size of the SN metastasis can serve as strong predictors of
NSN tumor involvement in breast cancer patients.
METHODS
Patient Selection
Between May 1998 and December 2001, all breast cancer
patients who underwent LM/SL as part of their breast can-
cer care were prospectively enrolled in a University of
North Carolina at Chapel Hill, IRB-approved, breast cancer
SN database. Review of this prospective database identified
260 patients with clinical T1 or T2 (5 cm) invasive breast
cancer who underwent successful LM/SL. Patients with
unsuccessful LM procedures were excluded.
Surgical Technique
All patients underwent LM/SL using a combined isosul-
fan blue dye (Lymphazurin, Hirsch Industries, Inc., Rich-
mond, VA) and technetium-labeled sulfur colloid
(99mTcSC) (Nicomed Amersham Canada Ltd., Oakville,
Ontario) technique, when technically feasible. The details of
this procedure have been well described previously.3,4,22
When the primary tumor was not palpable, patients under-
went preoperative needle localization with subsequent ul-
trasound-guided 99mTcSC injection performed in the mam-
mography suite. For patients with high upper outer quadrant
lesions, 99mTcSC was used at the discretion of the operating
surgeon. Routine preoperative lymphoscintigraphy was not
performed. All patients underwent intraoperative LM with
isosulfan blue dye (Lymphazurin). Intraoperatively, a cur-
vilinear axillary incision was made using a hand-held Gei-
ger counter to identify the area with the greatest number of
counts per second. The underlying tissue was carefully
dissected until a blue-stained lymphatic channel was iden-
tified. This channel was then followed proximally and dis-
tally until a blue node was located. If the ratio of the ex vivo
SN counts to the background counts was less than 10:1 after
removal of the SN, the dissection was continued to identify
and remove any additional radioactive and/or blue SNs.
The first 74 patients were part of our institutional SN
validation trial and underwent LM/SL followed by imme-
diate completion ALND. For the 186 subsequent patients,
ALND was offered as a delayed procedure to all patients
with a tumor-involved SN. After completion of the valida-
tion trial, patients with a tumor-free SN received no further
axillary therapy.
Handling and Histopathologic
Examination of the SN and NSN
Our protocol for handling and histopathologic examina-
tion of the SN and its evolution have been described pre-
viously in detail.22 Each SN was bivalved and subsequently
sliced at intervals of 1.0 mm or less. Alternating slices were
sent to the University of North Carolina Lineberger Com-
prehensive Cancer Center Tissue Procurement and Analysis
Core Facility for future studies and to surgical pathology for
permanent gross and histopathologic evaluation. The slices
retained by surgical pathology were then serially sectioned
and stained with hematoxylin-eosin (H&E). Immunohisto-
chemical (IHC) cytokeratin stain, CAM 5.2 (Becton Dick-
inson, San Jose, CA), was used routinely for patients with
invasive lobular carcinoma and selectively for all other
tumor types.
The NSNs from the 74 patients who were part of our SN
validation trial were serially sectioned and examined with
H&E and IHC stains in a similar fashion to the SN. The
NSNs from the subsequent 186 patients were examined at a
minimum of one H&E-stained section per node.
Statistical Methods
Logistic regression was used to test the association be-
tween NSN tumor status and several clinical and histopatho-
logic factors, including gender, age, number of tumor-in-
volved SNs, size of primary tumor, size of SN metastasis,
lymphovascular invasion, and ECE. Each factor was first
tested individually for a significant association with NSN
status. Continuous variables were analyzed using a univar-
iate logistic regression model. Dichotomous variables were
analyzed using the Pearson chi-square test (for ECE) or
Fisher exact test (for gender). Significant univariate factors
were then included in a multivariate logistic regression
model. Logistic regression analyses were performed using
the PROC LOGISTIC procedure in SAS, Version 8.02
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(SAS Institute, Cary, NC). Pearson chi-square and Fisher
exact tests were performed using the SAS PROC FREQ
procedure.
Information about presence or absence of LVI was miss-
ing for 10 patients. On preliminary testing, LVI did not
appear to have statistical significance or to significantly
impact the multivariate analysis. As a result, LVI was
dropped from the analysis to allow for inclusion of the
additional patients and expansion of the dataset. Size of the
SN metastasis was missing for two patients, so the final
multivariate analysis was performed on a total of 68 of the
70 patients with a tumor-involved SN who underwent
ALND.
RESULTS
A total of 260 patients (256 women, 4 men) with clinical
T1 or T2 breast cancer underwent 263 LM/SL procedures;
three women had bilateral disease. Their mean age was 56
years (range 26–91 years). The mean tumor size was 1.85
cm (range 0.1–11.3 cm).
An average of 2.0 SNs (range 1–8) were removed per
patient. The SN contained tumor in 74 (28.1%) cases. Pa-
tients with SN metastases had, on average, 1.6 tumor-
involved SNs (range 1–6). The mean size of SN metastasis
was 6.9 mm (range 0.01–25 mm). ECE of the SN metastasis
was present in 24.3% (18/74) of patients with a tumor-
involved SN.
Seventy of the 74 patients with a tumor-involved SN
underwent completion ALND before systemic adjuvant
therapy. Two elderly patients with small primary tumors
declined further axillary treatment after LM/SL. The other
two patients had synchronous gastrointestinal and breast
malignancies. One patient underwent neoadjuvant chemo-
therapy after colon resection, core breast biopsy, and LM/
SL; she ultimately underwent ALND after neoadjuvant ther-
apy. The other patient went directly to systemic adjuvant
therapy after primary tumor resections and LM/SL; she
never received a completion ALND.
NSN tumor involvement was present in 41.4% (29/70) of
patients with a tumor-involved SN who underwent ALND
before systemic adjuvant therapy. On univariate analysis,
size of the primary tumor and size of the SN metastasis,
both examined as continuous variables, were significantly
associated with NSN tumor involvement (P  .03 and P 
.003, respectively; Table 1). ECE of the SN metastasis was
also significantly associated with NSN tumor involvement
on univariate analysis: 78% of patients with ECE of the SN
metastasis had NSN tumor involvement, while only 29% of
patients without ECE of the SN metastasis had NSN me-
tastases (P  .0003). Additionally, ECE of the SN metas-
tasis was significantly associated with a greater total number
of tumor-involved axillary nodes (7.6 vs. 2.5, P  .006).
On multivariate analysis, only ECE of the SN metastasis
was significantly associated with NSN tumor involvement
(P  .01, odds ratio 6.04 [1.50, 24.22]; Table 2). Patients
with NSN tumor involvement tended to have larger SN
metastases (9.4 mm vs. 4.9 mm), but this difference was not
statistically significant on multivariate analysis. However,
when ECE of the SN metastasis was excluded from the
multivariate analysis, size of the SN metastasis was signif-
icantly associated with NSN tumor involvement (P  .02;
Table 3).
DISCUSSION
The widespread use of LM/SL for breast cancer is allow-
ing patients with T1 and T2 (5 cm) tumors and a tumor-
free SN to avoid the short- and long-term morbidity of
completion ALND. Unfortunately, completion ALND is
still necessary to determine the histopathologic tumor status
of the NSN in patients with a tumor-involved SN. For a
large percentage of these patients (27–68%)2,3,5,6,8 with a
tumor-involved SN, no NSN metastases will be identified.
Table 1. TESTING UNIVARIATE FACTORS
VS. NSN TUMOR INVOLVEMENT
P Value
ECE .0003
Size of SN metastasis .0032
Size of primary tumor .0289
Age .2606
# of tumor-involved SN .2005
Gender .3969
Table 2. TESTING MULTIVARIATE
FACTORS VS. NSN TUMOR
INVOLVEMENT
P Value Odds Ratio
ECE .0112 6.04 (1.50, 24.22)
Size of SN metastasis .0896 1.105 (0.98, 1.24)
Size of primary tumor .1152 1.31 (0.94, 1.84)
Age .7056 0.99 (0.94, 1.04)
# of tumor-involved SN .6149 0.83 (0.41, 1.70)
Gender .9873 0.001 (0.001, 999)
Table 3. TESTING MULTIVARIATE
FACTORS VS. NSN TUMOR
INVOLVEMENT (ECE EXCLUDED)
P Value Odds Ratio
Size of SN metastasis .0188 1.14 (1.02, 1.28)
Size of primary tumor .1311 1.27 (0.93, 1.74)
Age .7980 0.99 (0.94, 1.04)
# of tumor-involved SN .8248 0.93 (0.50, 1.73)
Gender .9868 0.001 (0.001, 999)
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Recognizing the opportunity to identify another group of
patients who might be able to avoid the morbidity of comple-
tion ALND, researchers began to look for predictors of NSN
tumor involvement in patients with a tumor-involved SN.
The initial attempts to identify predictors of NSN tumor
involvement demonstrated size of the primary tumor and
size of the SN metastasis as potential predictors of NSN
tumor involvement.9,10 Chu et al.9 examined multiple clin-
ical and histopathologic characteristics in an attempt to find
predictors of NSN tumor involvement in patients with a SN
metastasis. Their study of 157 women demonstrated that a
primary tumor larger than 2.0 cm and a SN metastasis larger
than 2.0 mm were significantly associated with NSN tumor
involvement (P  .01 and P  .0001, respectively). Simi-
larly, Reynolds et al.10 examined several clinical and his-
topathologic characteristics from 60 patients with primary
breast cancer and a SN metastasis. They confirmed that a
primary tumor larger than 2.0 cm and a SN metastasis larger
than 2.0 mm were significantly associated with NSN tumor
involvement (P  .0004 and P  0.002, respectively).
Several subsequent studies have shown size of the SN
metastasis11–14,17–19 and size of the primary tumor11–17 to
be associated with NSN tumor involvement. Weiser et al.,11
in an analysis of 206 patients with a tumor-involved SN,
found that both size of the SN metastasis and size of the
primary tumor were significantly associated with NSN tu-
mor involvement on multivariate analysis (P  .007 and
P  .0002, respectively). Similarly, Kamath et al.,12 in an
examination of 101 patients with a tumor-involved SN,
found that while 58.3% of patients with a macrometastasis
(2.0 mm) had NSN tumor involvement, only 15.2% of
patients with an SN metastasis 2.0 mm or smaller had NSN
tumor involvement (P  .001). They also confirmed that
size of the primary tumor was significantly associated with
NSN tumor involvement (P  .005).
Overall, size of the SN metastasis and size of the primary
tumor have been consistently identified as predictors of
NSN tumor involvement. Unfortunately, neither of these
characteristics, alone or in combination, has been demon-
strated to be a strong enough predictor of NSN tumor
involvement to identify a subset of patients who can safely
forgo ALND. As a result, the search for predictors of NSN
tumor involvement in patients with a tumor-involved SN
has continued.
In 1999, we began investigating how factors historically
reported to be prognostic for breast cancer patients trans-
lated to breast cancer patients treated in the SN era. Ac-
cordingly, we considered Fisher et al.’s23 observation that
ECE of axillary lymph node metastases is a valuable prog-
nostic factor in breast cancer patients. In Fisher’s original
study of 158 patients with axillary node metastases, a sig-
nificant correlation existed between the presence of ECE
and tumor involvement of more than three axillary nodes
(P  .002). Many other studies have subsequently con-
firmed that the presence of ECE of axillary node metastases
is significantly related to the total number of tumor-involved
axillary nodes in breast cancer patients.24–30
Our initial study,21 presented to the Society of Surgical
Oncology in 2000, was the first to examine the significance
of ECE in the SN era. We examined ECE of the SN
metastasis as a potential predictor of NSN tumor involve-
ment. On multivariate analysis, we demonstrated that ECE
of the SN metastasis was significantly associated with NSN
tumor involvement (P  .041). Additionally, patients with
ECE of the SN metastasis had a greater total number of
tumor-involved axillary nodes than patients without ECE
(P  .006).
Our current expanded dataset continues to support the
strong association between ECE of the SN metastasis and
NSN tumor involvement (P  .0003). While patients with
no evidence of ECE of the SN metastasis had an average of
2.5 tumor-involved axillary nodes, patients with ECE of the
SN metastasis had an average of 7.6 tumor-involved axillary
nodes. This association was highly statistically significant
(P  .0061).
Only two other published studies included ECE of the SN
metastasis in their examination of predictors of NSN tumor
involvement. Palamba et al.,20 in a study of 230 patients
with a tumor-involved SN, found ECE of the SN metastasis
to be significantly associated with NSN tumor involvement
(P  .001). Additionally, they found that ECE of the SN
metastasis was significantly associated with a greater total
number of tumor-involved axillary nodes (P  .001). Sim-
ilarly, Abdessalam et al.,18 in an examination of 100 pa-
tients with a tumor-involved SN, found that 84% of patients
with ECE of the SN metastasis had NSN tumor involve-
ment, while only 25% of patients without ECE had NSN
tumor involvement (P  .001).
While only three groups have examined ECE of the SN
metastasis as a potential predictor of NSN tumor involve-
ment, all three have demonstrated that ECE of the SN
metastasis is a powerful predictor of NSN metastases. Since
Fisher et al.’s23 initial report on ECE of axillary nodal
metastases, clinicians have felt that tumors demonstrating
ECE of the axillary nodal metastases represent a more
biologically aggressive subset of breast cancers. The ability
of nodal metastases to recruit degradation factors that per-
mit the tumor to break through the lymph node capsule
represents a very aggressive breast cancer tumor biology.
Our current study suggests that this aggressive biologic
feature far outweighs any other clinical or histopathologic
factors examined as a predictor of the total axillary nodal
tumor burden.
We were unable to confirm the associations between size
of the SN metastasis and size of the primary tumor and NSN
tumor involvement that have been previously reported. It is
important to note, however, that previous studies demon-
strating these associations did not consider ECE of the SN
metastasis in their analyses.9–12 While in our current study
both size of the SN metastasis and size of the primary tumor
were significantly associated with NSN tumor involvement
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on univariate analysis, these variables lost their significance
on multiple logistic regression models that included ECE.
However, when ECE was excluded from our multivariate
analysis, size of the SN metastasis was significantly asso-
ciated with NSN tumor involvement. This serves to empha-
size ECE of the SN metastasis as a predictor of NSN tumor
involvement. Until a superior predictor of NSN tumor in-
volvement is identified, we believe that ECE of the SN
metastasis should serve as the cornerstone for all future
multivariate analyses.
The clinical implications of this data are important. Due
to the high likelihood of extensive axillary tumor burden, all
breast cancer patients with ECE of the SN metastasis should
undergo a completion ALND. Conversely, patients with
small SN metastases and no evidence of ECE are highly
unlikely to harbor NSN metastases. As a result, the role of
completion ALND in these patients is controversial. This
important clinical question is being asked by the American
College of Surgeons Oncology Group trial Z0011 (Protocol
ACOSOG-Z0011. Phase III Randomized Study of Axillary
Lymph Node Dissection in Women With Stage I or IIA
Breast Cancer Who Have a Positive Sentinel Node, A. E.
Giuliano, principal investigator). In this trial, patients with a
tumor-involved SN are randomized to completion ALND or
no additional axillary therapy. If this trial fails to demon-
strate a survival advantage for patients undergoing ALND,
then completion ALND for patients with a tumor-involved
SN and no evidence of ECE may become obsolete, sparing
many patients the short- and long-term morbidity associated
with ALND.
CONCLUSIONS
Consistent with the historical experience from ALND
specimens, ECE of the SN metastasis is strongly associated
with a greater total number of tumor-involved axillary
nodes. ECE is a biologic marker of aggressive nodal dis-
ease. Consequently, patients with ECE of the SN metastasis
are highly likely to have NSN tumor involvement. As a
result, completion ALND should always be recommended
to patients with ECE of the SN metastasis, independent of
other clinical and histopathologic factors, including size of
the primary tumor and size of the SN metastasis.
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Discussion
DR. WILLIAM C. WOOD (Atlanta, GA): I first would congratulate the
continued outworkings of the major contribution made by Drs. Giuliano
and Morton to the entire approach that we take today to early breast cancer
with the use of sentinel node mapping and the identification of the majority
of women who do not have clinically involved nodes and do not need a
axillary dissection. I would particularly like to congratulate the authors
today, who were the first to describe extracapsular extension of metastases
as the major prognostic factor that it is in telling us what the other lymph
nodes are likely to be bearing. This was first presented at the Society of
Surgical Oncology. They now have a confirmatory larger study, and two
other authors have looked for the same thing and found it as well. So I think
they have not only described this, it is now an established finding.
Not only have they done this, they have analyzed it very elegantly
statistically. I guess I cavil, and apologize for being so picky, but as elegant
as the statistics are, I would like to see the actual data.
I would be very interested in knowing, for example, of the 18 patients
with extracapsular extension, what percent had nonsentinel node involve-
ment versus the 56 patients who did not have extracapsular extension, what
percent of those patients had positive nonsentinel nodes? The number of
involved nonsentinel nodes was three times as great in those with extra-
capsular extension. The question is, what are the varying percentages?
Second, we have found in looking at long-term prognosis a difference
between patients who have extracapsular extension, sort of gangbusters
breaking out through the wall of the lymph node that is apparent on gross
exam, and those sections you showed us that microscopically can be
demonstrated to have breakthrough but when it is not grossly apparent. Did
you find this? Have you looked for this in your studies?
Finally, a question as to the significance that is very impressive of
extracapsular extension. This clearly represents a summation of several
biologic factors of aggressiveness, just as lymph node numbers remain
important because they are results of metastatic potential, unlike the things
we find in the primary tumor. So lymph node number remains very
important. Do you think it is possible that lymph node extension may
actually overwhelm the number of involved lymph nodes as a prognostic
factor for the late outcome of women?
DR. CHARLES E. COX (Tampa, FL): I congratulate the authors on the
compilation of yet another excellent series of breast cancer patients which
have been managed with sentinel node mapping and selective lymphade-
nectomy. We have now entered a new era of breast cancer management
where sentinel lymph node mapping has become the standard of care in
over 70% of cases treated at the major cancer centers in the United States,
as reported to the NCCN data registry for breast cancer. With worldwide
data in excess of 15,000 reported cases validating the technique, little
question remains as to the use of the technique for axillary nodal staging.
Questions such as those addressed by the authors of this manuscript will
begin to refine the use of sentinel node mapping for breast cancer. In their
series of 260 patients in which 74, or 28%, had positive sentinel nodes, 18
of the 70, or 29%, demonstrated extracapsular extension, with a mean of
7.6 positive nodes per patient.
The authors have struck a familiar theme, which antedated sentinel node
mapping, by trying to predict which patients may not need complete node
dissection. Indeed, they have concluded the opposite; that is, the group of
patients which definitely needs a complete axillary lymph node dissection.
The data are clear that patients with extracapsular extension need a node
dissection. How might that information be used to modify the treatment
strategy for this group of patients with extracapsular extension of nodal
disease?
From this data one might conclude that all patients with extracapsular
extension of the sentinel node would be candidates for neoadjuvant che-
motherapy followed by complete node dissection. Clearly patients with this
magnitude of nodal involvement will receive adjuvant chemotherapy, one
third of which will be pathologically cleared of their axillary disease by
that chemotherapy and in addition will have statistically improved survival.
My questions: Should extracapsular extension found in the sentinel node
be used to stratify patients for treatment with neoadjuvant chemotherapy?
Will complete axillary node dissection at the termination of the treatment
be able to evaluate pathologic clearance of nodal disease as a means of
determining prognostic stratification? Better stated, did all patients with
extracapsular extension of the sentinel node have nonsentinel nodes which
contained tumor?
Again I congratulate the authors for looking to the next level of ques-
tions of how the sentinel node data may be used for treatment strategy. I
encourage all who manage breast cancer to put behind them the notion of
who will not need an axillary node dissection and embrace lymphatic
mapping. It is clear that those with negative sentinel nodes do not need
axillary node dissection while those with positive sentinel nodes do, at least
until the American College of Surgeons Z0011 randomized trial of node
dissection based on a positive sentinel node is completed.
DR. KELLY M. MCMASTERS (Louisville, KY): In an analysis of over
2,000 patients with clinical stage T1 and T2 breast cancers, we found that
overall 37% of the patients had positive nonsentinel nodes when the
sentinel node was positive. These are real positive nonsentinel nodes
identified on routine pathology with H&E staining. This is with a median
tumor size in the same range of T1c.
Although we did not have data on the size of sentinel node metastasis,
which is very clearly important, we couldn’t identify any subsets of
patients with a minimal risk of nonsentinel node metastasis when the
sentinel node was positive.
So my question is, could you identify any population of patients with a
positive sentinel node who had a 0% chance of nonsentinel node
metastasis?
DR. DAVID W. OLLILA (Chapel Hill, NC): Dr. Wood and Dr. Cox, if you
look at our patients with extracapsular extension of the sentinel node, 78%
of those patients had nonsentinel node metastases. Conversely, if you
looked at our patients that didn’t have extracapsular extension of the
sentinel node, only 29% of those patients had a nonsentinel node
metastasis.
And I think that dovetails into what Dr. McMasters was asking, can you
identify a subset of patients that are at such a low risk to have disease in
the remainder of the axilla that they don’t need axillary dissection? And the
answer is No. No matter what the statisticians did looking at the variables,
dichotomous or continuous variables, we were not able to come up with a
subset of patients that you could obviate the need for axillary dissection.
Conversely, though, we feel very strongly that the patients with ECE of the
sentinel node metastasis should have a mandatory axillary dissection.
Dr. Wood, regarding your question regarding gross versus microscopic,
we have not looked at it that way. I would like to go back, just as we have
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tried to quantitate the volume of the nodal metastasis, to try to quantitate
the volume of extracapsular extension. Is this a 2-mm break in the node, or
is one half or 75% of the node totally involved?
With regards to the absolute number of nodes involved, we need longer
follow-up. I think if we look at this data set 3 years, 4 years, 5 years from
now, I think we are going to have a better answer about the biology of
patients with extracapsular extension, because we have been treating them
as best we can in a routine manner in conjunction with our medical
oncology and surgical oncology colleagues.
With regards to your question, Dr. Cox, the issue of the role of sentinel
lymph node in patients with locally advanced breast cancer in conjunction
with neoadjuvant chemotherapy is a very hot topic. Two weeks ago at the
American College of Surgeons Oncology Group meeting in Phoenix, there
was a very lively discussion regarding the role of a sentinel node: Should
it come before the initiation of neoadjuvant chemotherapy? Should it come
after the initiation of chemotherapy?
I think doing the sentinel node up front gives you insight into the
biology, and now our medical oncology colleagues can tailor or plan what
they are going to do and how much. I think it is an excellent idea to add
different factors up front so we can learn as much biology. Because the
M. D. Anderson data are very clear, the patients that do the best are the
ones that have no axillary disease at the end of their therapy.
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